Nasdaq cprx.

Find the latest Institutional Holdings data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.

Nasdaq cprx. Things To Know About Nasdaq cprx.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Greetings and welcome to the Catalyst Pharmaceuticals Fourth Quarter and Full Year 2022 ...Catalyst Pharmaceuticals ( NASDAQ: CPRX) is a commercial-stage biopharmaceutical entity dedicated to in-licensing, developing, and marketing novel treatments for rare and challenging diseases ...See the latest Catalyst Pharmaceuticals Inc stock price (CPRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.14 jam yang lalu ... Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and ...

Nov 30, 2023 · NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, News & Analysis Should You Buy or Sell Catalyst Pharmaceuticals Stock? Get The Latest CPRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Should You Buy or Sell Catalyst Pharmaceuticals Stock? Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 70% over the last three months. Given the company's impressive performance, we ...

Catalyst also expects a cash balance of $191 million as of 2021-end, without any funded debt. For 2022, the company expects total revenues for 2022 in the range of $195-$205 million, suggesting a ...January 24, 2023 — 12:26 pm EST. Written by Zacks Equity Research for Zacks ->. Shares of Catalyst Pharmaceuticals CPRX were down 29.0% on Jan 24 after management announced that it had received ...

Research Catalyst Pharmaceuticals' (Nasdaq:CPRX) stock key valuation metrics while comparing it with its industry peers & market side by side. Dashboard Markets Discover Watchlist Portfolios Screener. Catalyst Pharmaceuticals, Inc. ... What is CPRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the ...(NASDAQ: CPRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.13%. What is CPRX's Price Target? According to 3 Wall Street analyst s that have issued a 1 year CPRX price target, the average CPRX price target is $25.00 , with the highest CPRX stock price forecast at $27.00 and the lowest CPRX …Per the terms of the agreement, CPRX is liable to make an upfront payment of $75 million to Santhera, along with a concurrent strategic equity investment of $15 million into Santhera.There are 542 funds or institutions reporting positions in Catalyst Pharmaceuticals. This is an increase of 82 owner (s) or 17.83%. Average portfolio weight of all funds dedicated to US:CPRX is 0. ...(NASDAQ: CPRX) Catalyst Pharmaceuticals currently has 106,582,857 outstanding shares. With Catalyst Pharmaceuticals stock trading at $12.85 per share, the total value of Catalyst Pharmaceuticals stock (market capitalization) is $1.37B .

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological ...

Nov 30, 2023 · The stock price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has plunged by -1.13 when compared to previous closing price of 14.21, but the company has seen a 2.26% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-09 that Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales […]

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has received a Notice Letter stating that Teva Pharmaceutical Industries Ltd (NYSE: TEVA) submitted an abbreviated marketing application to the FDA for ...Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ETCompany Participants. Patrick McEnany - Chairman, Chief Executive Officer. Alicia Grande - Vice ...CPRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Catalyst Pharmaceuticals, Inc. is based on the …Mar 16, 2023 · Catalyst Pharmaceuticals, Inc. CPRX reported earnings of 22 cents per share for the fourth quarter of 2022, marginally beating the Zacks Consensus Estimate of 21 cents. Earnings were also higher ... Catalyst Pharmaceuticals, Inc. CPRX announced that it will invest heavily in Research and Development (R&D), including acquiring earlier-stage opportunities, and expand its product portfolio ...Allspring Global Investments Holdings LLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 21.7% in the second quarter, according to the company in its most ...Starbucks’ (NASDAQ:SBUX) 100% Return Could Be Coming At A Cost Dec 2, 2020 Tesla Inc., (NASDAQ:TSLA) is Getting Stronger, and it may be Time to Reevaluate Feb 11, 2022 Calculating The Fair Value ...

Find the latest Insider Activity data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. Catalyst Pharmaceuticals had non-GAAP profits of 41 cents, a full dime a share over the consensus. On a GAAP basis, earnings were 26 cents a share for the quarter, an improvement of 117% from ...Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.The latest price target for Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price ...Catalyst Pharmaceuticals (NASDAQ: CPRX) $14.05 (-1.1%) -$0.16 Price as of November 29, 2023, 4:00 p.m. ET Financial Health Earnings Transcripts Related Stocks Key Data Points Current Price $14.05...

Fintel reports that on August 11, 2023, Cantor Fitzgerald maintained coverage of Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight recommendation. Analyst Price Forecast Suggests 52.12% Upside

NasdaqCM:CPRX Insider Trading Volume August 29th 2021. I will like Catalyst Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of growing companies with ...The average twelve-month price prediction for Catalyst Pharmaceuticals is $24.75 with a high price target of $27.00 and a low price target of $24.00. Learn more on CPRX's analyst rating history. Do Wall Street analysts like Catalyst Pharmaceuticals more than its competitors? Analysts like Catalyst Pharmaceuticals more than other Medical companies.While the historical EPS growth rate for Catalyst is 42.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 56% this year, crushing the industry ...Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with..Analyst Andrew Fein of H.C. Wainwright has scored a 100% success rate on his views on Catalyst Pharmaceuticals (NASDAQ:CPRX) stock.Fein is an expert in tracking U.S.-based Healthcare companies ...Jan 24, 2023 · January 24, 2023 — 12:26 pm EST. Written by Zacks Equity Research for Zacks ->. Shares of Catalyst Pharmaceuticals CPRX were down 29.0% on Jan 24 after management announced that it had received ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ETCompany Participants. Alicia Grande - VP, CFO, and Treasurer. Patrick J. McEnany - Chairman ...

CPRX CPRX AFTER HOURS QUOTE CPRX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...

The average twelve-month price prediction for Catalyst Pharmaceuticals is $24.75 with a high price target of $27.00 and a low price target of $24.00. Learn more on CPRX's analyst rating history. Do Wall Street analysts like Catalyst Pharmaceuticals more than its competitors? Analysts like Catalyst Pharmaceuticals more than other Medical companies. Earnings vs Savings Rate: CPRX's forecast earnings growth (25.8% per year) is above the savings rate (2.2%). Earnings vs Market: CPRX's earnings (25.8% per year) are forecast to grow faster than the US market (14.7% per year). High Growth Earnings: CPRX's earnings are expected to grow significantly over the next 3 years.The latest price target for . Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by Cantor Fitzgerald on August 22, 2023.The analyst firm set a price target for $27.00 expecting CPRX to rise to ...Catalyst Pharmaceuticals CPRX is expected to report its fourth-quarter 2022 results sometime in the middle of March. Catalyst Pharmaceuticals’ earnings surprise history has been mixed so far ...Mar 10, 2023 · Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ... Aug 29, 2021 · NasdaqCM:CPRX Insider Trading Volume August 29th 2021. I will like Catalyst Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of growing companies with ... Catalyst Pharma (NASDAQ:CPRX) is a $1.6bn market cap (at the time of writing) Florida based commercial stage biotech that markets and sells a single product - the neuronal potassium channel ...The $210.13 million and $294.89 million estimates for the current and next fiscal years indicate changes of +49.2% and +40.3%, respectively. Catalyst reported revenues of $57.24 million in the ...The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...Catalyst Pharmaceuticals, Inc. CPRX reported earnings of 20 cents per share for the third quarter of 2022, beating the Zacks Consensus Estimate of 19 cents. Earnings were also higher than our ...Dec 1, 2023 · Get the latest Catalyst Pharmaceuticals, Inc CPRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... NASDAQ data is at least 15 minutes delayed. That number of contracts represents approximately 884,100 underlying shares, working out to a sizeable 52.9% of CPRX's average daily trading volume over the past month, of 1.7 million shares.

CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ...Find the latest SEC Filings data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has received a Notice Letter stating that Teva Pharmaceutical Industries Ltd (NYSE: TEVA) submitted an abbreviated marketing application to the FDA for ...CORAL GABLES, Fla. , Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany , Founder, Chairman and CEO of Catalyst, has been bestowed the 2023 Lifetime. Oct 13, 2023.Instagram:https://instagram. losers and gainers stocksbest healthcare plans in georgiayaskawa electric corporationare municipal bonds a good investment Find the latest Institutional Holdings data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.This value model looks for companies with high return on capital and earnings yields. CATALYST PHARMACEUTICALS INC ( CPRX) is a small-cap growth stock in the Biotechnology & Drugs industry. The ... trusted pals pet insurance reviewsis surge trader legit Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Earnings Report Date | Nasdaq. Created with Sketch. *The upcoming earnings date is derived from an algorithm based on a company's historical ... ai penny stocks to buy The latest price target for Catalyst Pharmaceuticals ( NASDAQ: CPRX) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price target for 27.00 expecting CPRX to ...For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ...